About Helios
Helios is a company based in Tokyo (Japan) founded in 2011. It operates as a HealthTech. Helios has raised $29.17 million across 2 funding rounds from investors including Nikon, European Union and Sumitomo Dainippon Pharma. The company has 65 employees. Helios offers products and services including iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells). Helios operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Blue Rock Therapeutics and Nicox, among others.
- Headquarter Tokyo, Japan
- Employees 65
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website healios.co.jp
- Social LinkedIn
- Legal Name Healios Kk
- Annual Revenue$663.81 K (USD)-81.43as on Dec 31, 2025
- Net Profit-$14.17 M (USD)47.65as on Dec 31, 2025
- EBITDA-$19.98 M (USD)-20.08as on Dec 31, 2025
- Total Equity Funding$29.17M (USD)
in 2 rounds
- Latest Funding Round$55.99K (USD), Grant
Jun 2019
- InvestorsNikon
& 2 more
- Employee Count65
Products & Services of Helios
Helios offers a comprehensive portfolio of products and services, including iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells).
Innovative therapies are developed using iPSC technology.
Treatments are created using somatic stem cells.
Cancer treatments are developed using NK cells.
Funding Insights of Helios
Helios has successfully raised a total of $29.17M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $55.99 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.17M
- Total Rounds 2
- Last Round Grant — $55,992
- First Round $29.17M
(Oct 2013)
- Investors Count 3
All 2 funding rounds of Helios with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $55,992 | Grant | – | – | |
| Oct 2013 | $29.17M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Helios
Helios has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Nikon, European Union and Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured. | 1897 | ds-pharma.com | Osaka, Japan | |
Nikon is recognized as a key technology solutions company. | 1917 | nikon.com | Minato, Japan |
Investor details for Helios
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Helios
Helios is a publicly listed company on the TSE with ticker symbol 4593 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 2015
- Listed onTSE: 4593
- Listed entityHealios KK
- Exchange sectorHealth technology
- ISINJP3835100003
- Share price302.00 JPY (+0.67% on the day) · 2026-10-09
- Market capitalisation40,934,681,610.00 JPY
- Price to earnings110.4
- EPS (diluted, trailing year)2.73 JPY
- Volume (last session)1,336,400
Financials of Helios
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 104.0M JPY | -2.22B JPY | -3.13B JPY |
| 2024 | 560.0M JPY | -4.24B JPY | -2.60B JPY |
| 2023 | 121.0M JPY | -3.82B JPY | -3.01B JPY |
| 2022 | 90.0M JPY | -5.17B JPY | -4.78B JPY |
| 2021 | 41.0M JPY | -4.91B JPY | -5.12B JPY |
Detailed financial statements for Helios
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Helios
4 dated milestones of Helios across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Helios is founded.
- Funding First funding round of $29.2M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $56K.
Competitors of Helios
Helios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Blue Rock Therapeutics and Nicox, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| bluerocktx.com | 2016 | Boston, United States | $225M | 138 | Stem cell therapies are developed for cardiovascular and neurological diseases. | |
| nicox.com | 1996 | Valbonne, France | $271.01M | – | Nitric oxide-based therapeutics for glaucoma and eye conditions are developed. | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| aspenneuroscience.com | 2018 | San Diego, United States | $224M | – | Provider of genomic-based personalised pluripotent stem cell therapy | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. | |
| perceivebio.com | 2021 | San Francisco, United States | $78M | – | Developer of therapeutics to treat diabetes and eye diseases | |
| alimerasciences.com | 2003 | Alpharetta, United States | $66.8M | 79 | Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. |
Detailed competitors of Helios
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Helios
The website of Helios (healios.co.jp) receives about 26.8K visits a month and ranks #899,069 among all websites worldwide, #1,080 in Biotechnology and Pharmaceuticals.
- Monthly visits26.8K
▼ 1% vs previous month
- Unique visitors10K
per month
- Global rank#899,069
among all websites
- Category rank#1,080
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit3.1
- Average visit2 min 11 sec
- DevicesDesktop 60% · Mobile 40%
Websites whose visitors overlap most with Helios. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ptglab.co.jp | ptglab.co.jp | 100% | – | #676,043 | – |
kyo-eye.org | kyo-eye.org | 61% | – | #1,348,363 | – |
| nipro.co.jp | 60% | 160.7K | #244,538 | View details | |
he-lios.co.jp | he-lios.co.jp | 31% | – | #3,685,191 | – |
news.yahoo.co.jp | news.yahoo.co.jp | 30% | – | #44 | – |
Latest news on Helios
Complete news archive for Helios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Helios
10 companies that operate in the same segment as Helios (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Helios
Helios was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Helios is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Helios is a funded company, having raised a total of $29.17M across 2 funding rounds to date. The company's 1st funding round was a Series A of $29.17M, raised on Oct 2013.
Helios has 65 employees.
Annual revenue of Helios is $663.81K as on Dec 31, 2025.
Helios is focused on the development of regenerative medicine therapies to expand treatment options for patients worldwide. The company operates in sectors such as iPSC regenerative medicine, somatic stem cell therapies, and cancer immunotherapy using NK cells. Solutions are being researched for conditions like age-related macular degeneration, liver diseases, stroke, and acute respiratory distress syndrome (ARDS). Innovative strategies are employed to deliver new treatment methods and hope to patients globally.
Helios's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Helios offers iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells).
Yes, Helios is publicly traded on TSE under the ticker symbol 4593.
Helios has 3 investors. Key investors include Nikon, European Union, and Sumitomo Dainippon Pharma.
Helios operates through Helios K.K..